Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Tracon Pharmaceuticals, Inc. (TCON)
Sector: Healthcare; Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-12-30 Ikarian Capital, LLC Member of 10% Group Buy 520,291 $9.61 $4,999,997 No
2020-11-11 Ikarian Capital, LLC Member of 10% Group Buy 34,000 $5.10 $173,269 No
2020-09-11 Ikarian Capital, LLC Member of 10% Group Buy 322,471 $3.28 $1,057,387 No
2020-09-11 Ikarian Capital, LLC Member of 10% Group Buy 322,471 $3.28 $1,057,387 No

Insider Smart

CEDAR FAIR L.P. (FUN) - Another crash victim, Cedar Fair L.P. took a deep dive from $54 to $13, insiders were confidence and eagerly jumped in around $27. With insiders on your side, this would be an easy add and hold to get your cost under $20. Stock is about to breach $40 in the coming weeks.

Insider Smart

SIMON PROPERTY GROUP (SPG) - Bottom fishing the crash could be intimidating, but it can be easier if you know insiders are on your side. Aeppel Glyn, Director of SPG played safe and bought shares in May at $50, but it is not late at all, the stock is now $90.